Search
Insilico Medicine has released an updated prospectus, solidifying its sprint towards becoming the first AI-powered innovative drug stock listed on the Main Board of the Hong Kong Stock Exchange, with Morgan Stanley, CICC, and GF Securities serving as joint sponsors. Positioned as a global frontrunner in AI-driven biotechnology, Insilico Medicine's Phase II clinical assets are advancing at a rapid pace. Its generative AI platform, Pharma.AI, has generated over 20 clinical or IND-stage assets, with 10 securing clinical trial approvals and 3 being licensed out in deals totaling more than $2 billion. The company's diverse portfolio encompasses drug discovery, software solutions, and exploration in non-pharmaceutical areas, with revenues steadily increasing from 2022 to 2024, gross margins annually climbing to 90.4%, and adjusted losses significantly narrowing.
-
C114 Communication Network -
Communication Home
